Medicine and Dentistry
Vosaroxin
100%
Acute Myeloid Leukemia
50%
Toxicity
25%
Cell Cycle
25%
Programmed Cell Death
25%
Monotherapy
25%
Hematologic Malignancy
25%
DNA Damage
25%
Neutropenia
25%
Platinum
25%
Ovarian Cancer
25%
S Phase
25%
DNA Topoisomerase (ATP Hydrolysing)
25%
Cytotoxic Agent
25%
Drug
25%
Chemotherapeutic Agent
25%
Gyrase Inhibitor
25%
Intercalating Agent
25%
G2 Phase Cell Cycle Checkpoint
25%
Naphthyridine Derivative
25%
Therapeutic Procedure
25%
Inpatient
25%
Pharmacology, Toxicology and Pharmaceutical Science
Vosaroxin
100%
Acute Myeloid Leukemia
50%
Toxicity
25%
DNA
25%
Neutropenia
25%
Monotherapy
25%
Platinum
25%
Ovary Cancer
25%
Cytotoxic Agent
25%
Drug
25%
Hematologic Malignancy
25%
Intercalating Agent
25%
DNA Topoisomerase (ATP Hydrolysing)
25%
Naphthyridine Derivative
25%
Gyrase Inhibitor
25%
Biochemistry, Genetics and Molecular Biology
Topoisomerase
50%
Apoptosis
25%
Solid
25%
S Phase
25%
Cell Cycle
25%
DNA Damage
25%
G2 Phase Cell Cycle Checkpoint
25%
Dose
25%
DNA
25%
Material Science
DNA
50%
Toxicity
25%
Cell Death
25%
Solid
25%
Cell
25%
Chemistry
Naphthyridine Derivative
25%